Prazosin Hydrochloride
Average across 65 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Bryant Ranch Prepack | repackager | 29 | SUPPLYING |
| Asclemed USA, Inc. | unknown | 18 | SUPPLYING |
| Alembic Pharmaceuticals Limited | unknown | 18 | SUPPLYING |
| Preferred Pharmaceuticals, Inc. | unknown | 16 | SUPPLYING |
| Aphena Pharma Solutions - Tennessee, LLC | unknown | 13 | SUPPLYING |
| REMEDYREPACK INC. | repackager | 13 | SUPPLYING |
| Novadoz Pharmaceuticals LLC | unknown | 10 | SUPPLYING |
| ANI Pharmaceuticals, Inc. | unknown | 10 | SUPPLYING |
| Proficient Rx LP | unknown | 7 | SUPPLYING |
| Teva Pharmaceuticals USA, Inc. | unknown | 7 | SUPPLYING |
| Lifestar Pharma LLC | unknown | 6 | SUPPLYING |
| Exelan Pharmaceuticals, Inc. | unknown | 6 | SUPPLYING |
| Aurobindo Pharma Limited | unknown | 6 | SUPPLYING |
| Mylan Pharmaceuticals Inc. | unknown | 6 | SUPPLYING |
| Marlex Pharmaceuticals Inc | unknown | 6 | SUPPLYING |
+ 15 more labelers
Shortages, recalls, and registration changes attached to this drug concept.
cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits. — Recalling firm: Appco Pharma LLC — U.S.A. Nationwide
cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits. — Recalling firm: Appco Pharma LLC — U.S.A. Nationwide
cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits. — Recalling firm: Appco Pharma LLC — U.S.A. Nationwide
Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit — Recalling firm: Amerisource Health Services LLC — Nationwide within the United States
Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit — Recalling firm: Amerisource Health Services LLC — Nationwide within the United States
Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit — Recalling firm: Amerisource Health Services LLC — Nationwide within the United States
CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots. — Recalling firm: Teva Pharmaceuticals USA, Inc — U.S. Nationwide
CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots. — Recalling firm: Teva Pharmaceuticals USA, Inc — U.S. Nationwide
CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots. — Recalling firm: Teva Pharmaceuticals USA, Inc — U.S. Nationwide
cGMP deviations: Temperature abuse — Recalling firm: Mckesson Medical-Surgical Inc. Corporate Office — USA nationwide.
Pill